TScan Therapeutics, Inc. TCRX 深 滬
已收盤 05-08 16:00:00 美东时间
1.26
+0.050
+4.13%
華盛通- 最 高1.34
- 今 開1.23
- 成交量 127.70万股
- 最 低 1.23
- 昨 收 1.21
- 總市值 7.57万
- 52周最高 2.57
- 市盈率 靜 --
- 換手率 2124.71%
- 52周最低 0.8824
- 委 比 3.24%
- 總股本 6.01万
- 歷史最高 14.71
- 量 比 1.62
- 振 幅 9.09%
- 歷史最低 0.8824
- 每 手 1
- 風險率 0.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 15.38 percent increase over losses of $(0.26) per share from
05-06 19:12
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
03-05 21:49
Earnings Breakdown: TScan Therapeutics Q4
TScan Therapeutics (NASDAQ:TCRX) announced its Q4 earnings on Wednesday, March ...
03-04 20:12
TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 26.53 percent. This is a 37.93 percent increase over losses of $(0.29) per share
03-04 20:10
TScan Therapeutics Completes Enrollment Into Cohort C Of ALLOHA Study
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting
02-26 20:15
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 6.9% to $1....
02-14 05:06
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
2025-12-05 01:20
